Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Impax Asset Management Group plc

Impax Asset Management Group plc grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 70.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 85,000 shares of the company’s stock after purchasing an additional 35,000 shares during the period. Impax Asset Management Group plc’s holdings in Neurocrine Biosciences were worth $9,794,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of NBIX. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences in the 2nd quarter valued at about $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $30,000. New Covenant Trust Company N.A. acquired a new stake in shares of Neurocrine Biosciences in the first quarter worth $32,000. EdgeRock Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $35,000. Finally, Plato Investment Management Ltd acquired a new stake in shares of Neurocrine Biosciences in the first quarter worth $41,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the topic of a number of recent research reports. Barclays decreased their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $131.00 to $159.00 in a report on Thursday, August 29th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Finally, Royal Bank of Canada decreased their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Price Performance

NBIX opened at $117.44 on Friday. The business has a 50 day simple moving average of $118.56 and a two-hundred day simple moving average of $132.81. The firm has a market capitalization of $11.89 billion, a price-to-earnings ratio of 31.49 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $107.84 and a one year high of $157.98.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.